Published Date: 02 Mar 2023
Although further research is needed, these tools may improve clinical management.
Read Full NewsCuda discussed the potential of the NIH toolbox to easily assess cognitive effects in clinical trials.
Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.
New findings from the LUMINA trial reveal AMX0114's safety in ALS patients, paving the way for further research and potential treatment advancements.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromodulation for Parkinson disease!
Asthma Biologic Adherence Shaped by Psychological, Clinical, Systemic Factors
Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia
Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA
1.
Compared to previous estimates, a greater number of patients participate in cancer treatment trials.
2.
Zebrafish models offer fast, effective guidance for personalized therapies for kids with high-risk cancer
3.
Let's Talk Breast Density; Cancer, Movies, and Music; Treatment-Induced Aging?
4.
Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.
5.
The diamonds that could find cancer
1.
Case Study: Genomic Medicine in Precision Oncology
2.
Everything You Need to Know About HTLV: A Comprehensive Guide
3.
Navigating the Evolving Landscape of Oncology Clinical Trials in the Era of Precision Medicine
4.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
5.
Can AI Become Our Oncologic Ally? A Look at Artificial Intelligence in Cancer Detection and Control
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment
2.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation